Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic aims to raise $1bn in note sale

This article was originally published in Clinica

Executive Summary

Medtronic is looking to raise around $1bn through a public note sale. Medtronic will offer $500m of its 2.625% senior notes, due 2016, and $500m of its 4.125% senior notes, due 2021. The firm intends to use the cash for general corporate purposes, which could include the repayment of debts. Last month, Minneapolis, Minnesota-based Medtronic recorded modest growth in its third fiscal quarter, and announced plans to cut up to 2,000 jobs in an attempt to control costs (www.clinica.co.uk, 22 February 2011). In other moves to reduce outgoings, it has also cancelled five contracts worth around $2bn with US healthcare group purchasing organisation (GPO) Novation (www.clinica.co.uk, 1 March 2011). Shortly after that, Medtronic also pulled out of its contract with another GPO, Premier, which covered spinal products. Medtronic now plans to sell these products directly to hospitals.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel